跳至主要内容
临床试验/NCT06282731
NCT06282731已完成早期 1 期

The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia After Medical Treatment

En Chu Kong Hospital1 个研究点 分布在 1 个国家目标入组 74 人开始时间: 2013年5月31日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
入组人数
74
试验地点
1
主要终点
Urine growth factors level

研究概览

简要总结

The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia after medical treatment.

详细描述

The prevalence of benign prostate hyperplasia, like medical illness such as hypertension, diabetes mellitus and stroke, increase by age. Benign prostate hyperplasia will cause bothersome lower urinary tract symptoms in the middle and aged male. Previous studies have showed that overactive bladder syndrome (urge, frequency, nocturia or urinary incontinence) has been considered as an important factor to predict successful treatment.

Urine nerve growth factor level, brain-derived neurotrophic factor and endothelium vascular growth factor have been proved as a simple and noninvasive biomarker for diagnosing overactive bladder. As a result, investigator will investigate the changes of these growth factors level in patients with benign prostate hyperplasia before and after three and six-months medical treatment. In addition, investigator can understand whether overactive bladder will have effects on successful medical treatment in patients with benign prostate hyperplasia.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • men with age 50~80 years old
  • maximal flowrate 5~15ml/sec
  • prostate size>20ml
  • urine amount>150ml
  • patient/family can sigh the inform concent

排除标准

  • prostate cancer or suspected prostate cancer(PSA>4ng/ml)
  • history of prostate surgery
  • free of active urinary tract infection in past 6 months
  • patient with any other serious disease considered by investigator not in the condition to enter trials

研究组 & 干预措施

urine growth factor

Other

Previous studies have showed that overactive bladder syndrome (urge, frequency, nocturia or urinary incontinence) has been considered as an important factor to predict successful treatment.

Urine nerve growth factor level, brain-derived neurotrophic factor and endothelium vascular growth factor have been proved as a simple and noninvasive biomarker for diagnosing overactive bladder.

干预措施: Silodosin (Drug)

结局指标

主要结局

Urine growth factors level

时间窗: One month after medical treatment

Check Urine growth factors level after one month

次要结局

  • Urine growth factors level(Three months after medical treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

ChungChengWang

Chief of Department of Urology

En Chu Kong Hospital

研究点 (1)

Loading locations...

相似试验